PRIMARY PERITONEAL CANCER

This study is testing whether new maintenance drugs can help women with recurrent ovarian cancer live longer without their cancer getting worse. After completing standard chemotherapy, participants will receive either the new drug combinations or standard care to see which works …

This study is testing a new combination of chemotherapy and a targeted drug called mirvetuximab soravtansine for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if giving this treatment before surgery is safe and effective at shrin…

This study is testing a new oral drug called ART0380 in people with advanced or metastatic solid tumors that have spread and are hard to treat. The main goals are to find the safest and most effective dose of ART0380 when given alone or combined with standard chemotherapy drugs, …

This study is testing whether a new targeted drug called mirvetuximab soravtansine, when combined with standard chemotherapy (carboplatin), can shrink tumors before surgery in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The treatment is designed to…

This study is testing a new experimental drug, REGN5668, alone and in several combinations with other cancer drugs, for people with advanced ovarian, fallopian tube, peritoneal, or uterine cancers that have progressed after standard treatments. The main goals are to find the safe…

This is the first study in people for a new oral medication called AVZO-021. It aims to find a safe dose and see if the drug can help control advanced solid tumors, including certain types of breast and ovarian cancer, when other standard treatments are no longer working. The stu…

This study is testing if adding an experimental drug called IMNN-001 to standard chemotherapy and bevacizumab is safe and more effective at controlling advanced ovarian, fallopian tube, or primary peritoneal cancer. Researchers will compare the two-drug standard treatment to the …

This early-stage study is testing whether combining two drugs, Cirtuvivint and Olaparib, is safe and tolerable for women with a specific type of ovarian cancer that has stopped responding to standard platinum-based chemotherapy. The trial will enroll about 50 women who have alrea…

This study is testing whether adding an experimental drug called TORL-1-23 to standard chemotherapy helps control advanced ovarian cancer before surgery. It will involve 60 women with newly diagnosed, advanced-stage ovarian, fallopian tube, or primary peritoneal cancer whose tumo…

This study is testing if a modified virus called Olvi-Vec, given directly into the abdomen, can help chemotherapy work better for women with ovarian cancer that has stopped responding to standard platinum drugs. Participants will be randomly assigned to receive either the virus f…

This study is testing a telehealth program called REVITALIZE to see if it can help reduce the severe fatigue that often interferes with daily life for people with advanced ovarian cancer who are taking PARP inhibitor medications. About 240 participants will be randomly assigned t…

This study aims to better understand how specific genetic features in ovarian cancer affect how patients respond to standard treatments. It will observe 1000 women with newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer across four Nordic countries. Researchers…